Capricor Therapeutics (CAPR) Stock News

A class action lawsuit alleges Capricor made false statements about modifying the statistical analysis plan for Deramiocel without FDA agreement before resubmitting the BLA. Class period Dec 17, 2025 to July 26, 2026. Lead plaintiff deadline is today, Sept 28, 2026.

Hagens Berman announced a September 28 lead plaintiff deadline in a securities class action against Capricor Therapeutics (CAPR). The suit alleges Capricor made misleading statements about clinical trial data and undisclosed changes to the statistical analysis plan for deramiocel, its Duchenne muscular dystrophy therapy. Shares fell 64% on July 27 after the FDA revealed the SAP modifications. The FDA extended the PDUFA decision date to November 22.

Rosen Law Firm reminds investors of the Sept. 28 lead plaintiff deadline for a securities class action against Capricor Therapeutics (CAPR). The lawsuit alleges false statements about undisclosed changes to the Deramiocel statistical analysis plan and FDA approval risks. Class period: Dec. 17, 2025 – July 26, 2026.

Piper Sandler upgraded AKAM, TEM, CAPR; Morgan Stanley upgraded HOOD; BofA downgraded PCG and EIX. Other changes include upgrades for TKO, DUOL, TDW, PK, NCDL, HTGC, TKR, COLB, SRE and downgrades for MYGN, MIAX, XHR. Price targets adjusted.